GENOME ANNOUNCEMENT
===================

*Streptomyces rimosus* is a Gram-positive, aerobic, filamentous actinobacterium. It was reported in 1950 and was patented ([@B1]) as the founder strain for the production of the antibiotic oxytetracycline (OTC) ([@B2]). Recombination was recognized ([@B3]) and a rudimentary genetic map was deduced ([@B4]). The pharmaceutical industry set out to improve the commercial productivity of OTC, deriving higher-titer genealogies that led to the contemporary industrial strains that are now responsible for the production of \>10^8^ kg of OTC annually. Stimulated by commercial interest over the years, a sophisticated genetics and molecular biology has been developed for *S. rimosus* ([@B5]). This announcement reports the derivation of data to enable the generation of a scaffold genome sequence for this important industrial species.

Genome sequencing of the *S. rimosus* type strain ATCC 10970 was carried out using a whole-genome shotgun sequencing approach performed on a Roche 454 GS Junior apparatus. Using three single-ended runs, we obtained 440,253 reads. The reads were assembled using Genome Sequencer *de novo* Assembler (version 2.7, Roche), which led to a final assembly of 453 contigs of \>500 bp. The total size of the assembly was 9.5 Mbp, with a mean contig size of 21 kbp (average, 17× coverage) and a G+C content of 71.88%. Automatic functional annotation results were obtained using the NCBI Prokaryotic Genome Annotation Pipeline (<http://www.ncbi.nlm.nih.gov/genomes/static/Pipeline.html>).

The draft genome of *S. rimosus* is estimated to have a total of 8,416 protein-coding genes, along with 66 tRNAs. The overall genome size is consistent with the physical map of *S. rimosus*, derived by pulsed-field gel electrophoresis ([@B6]). It is also within the range of other published streptomycete genome sequences. Three gene clusters associated with the production of previously reported secondary metabolites \[OTC ([@B7]), rimocidin ([@B8]), and desferrioxamine C ([@B9])\] are readily identified within the sequence, in addition to around 45 other putative secondary metabolite biosynthetic clusters whose functions remain to be elucidated ([@B10]). The strain is lysogenic for phages RP2 and RP3, with the DNA sequences corresponding to the restriction maps published previously ([@B11]). The genome sequence is also likely to include at least one giant (387 kb) linear plasmid known to be present in *S. rimosus* ([@B12]).

Sequencing of *S. rimosus* ATCC 10970 provides a scaffold from which to investigate and understand how mutation results in higher titers of OTC.

Nucleotide sequence accession numbers. {#h1}
--------------------------------------

The *S. rimosus* ATCC 10970 Whole Genome Shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession no. [ANSJ00000000](ANSJ00000000). The version described in this paper is the first version, [ANSJ01000000](ANSJ01000000).
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